News & Insights
Stay Informed With Our Latest Updates
Explore our comprehensive collection of news and in-depth insights spanning practice areas, industries, and regions.
Firm News February 17, 2026
Gibson Dunn Advised Galecto on Public Offering of Common Stock
Gibson Dunn advised Galecto, Inc. on its public offering of common stock, which generated aggregate gross proceeds to the company of approximately $316 million.
Firm News December 17, 2025
Gibson Dunn Advising Yarrow Bioscience on Merger with VYNE Therapeutics and Concurrent $200 Million Financings
Gibson Dunn is advising Yarrow Bioscience on its merger with VYNE Therapeutics and concurrent $200 million financings
Firm News November 17, 2025
Gibson Dunn Represented Cogent Biosciences in Concurrent Public Offerings of Common Stock and Convertible Notes with Aggregate Gross Proceeds of $575 Million
Gibson Dunn represented Cogent Biosciences, Inc., a clinical-stage biotechnology company, in concurrent public offerings of common stock and convertible notes expected to result in aggregate gross proceeds of $575 million to Cogent
Firm News October 28, 2025
Gibson Dunn Advised X4 Pharmaceuticals on Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Gibson Dunn advised X4 Pharmaceuticals on its public offering of common stock and full exercise of the underwriters’ option to purchase additional shares for gross proceeds of $155.3 million
Firm News October 10, 2025
Gibson Dunn Represented Apogee Therapeutics on $345 Million Offering of Common Stock and Pre-Funded Warrants
Gibson Dunn represented Apogee Therapeutics, Inc., a clinical-stage biotechnology company, in a public offering of 8,048,782 shares of common stock, including the full exercise of the underwriters' option to purchase an additional 1,097,561 shares.
Firm News October 31, 2024
Gibson Dunn Advises Jade Biosciences on Merger with Aerovate Therapeutics, Inc. and Concurrent Private Placement
Gibson Dunn is advising Jade Biosciences on its merger with Aerovate Therapeutics, Inc. and the concurrent $300 million private placement of shares of its common stock and pre-funded warrants to a syndicate of healthcare investors.